DOP2011000258A - Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata - Google Patents
Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostataInfo
- Publication number
- DOP2011000258A DOP2011000258A DO2011000258A DO2011000258A DOP2011000258A DO P2011000258 A DOP2011000258 A DO P2011000258A DO 2011000258 A DO2011000258 A DO 2011000258A DO 2011000258 A DO2011000258 A DO 2011000258A DO P2011000258 A DOP2011000258 A DO P2011000258A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- piridazina
- prostata cancer
- triazolo derivatives
- triazolo
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La invención se refiere a compuestos bicíclicos de Fórmula I en donde , R1, R2, L1, L2, J, Y, k, n, p y r son tal como se definen en la descripción. La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en el tratamiento de afecciones asociadas con el receptor de andrógenos, en particular el cáncer de próstata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15122109P | 2009-02-10 | 2009-02-10 | |
US18776609P | 2009-06-17 | 2009-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000258A true DOP2011000258A (es) | 2011-09-30 |
Family
ID=42115693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000258A DOP2011000258A (es) | 2009-02-10 | 2011-08-10 | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata |
Country Status (27)
Country | Link |
---|---|
US (2) | US8258140B2 (es) |
EP (1) | EP2396333B1 (es) |
JP (1) | JP5059977B2 (es) |
KR (1) | KR20110113755A (es) |
CN (1) | CN102388048B (es) |
AR (1) | AR075383A1 (es) |
AU (1) | AU2010212590B2 (es) |
CA (1) | CA2749926A1 (es) |
CL (1) | CL2011001920A1 (es) |
CO (1) | CO6410299A2 (es) |
CR (1) | CR20110427A (es) |
CU (1) | CU20110158A7 (es) |
DO (1) | DOP2011000258A (es) |
EA (1) | EA019647B1 (es) |
EC (1) | ECSP11011257A (es) |
ES (1) | ES2427917T3 (es) |
HK (1) | HK1164870A1 (es) |
IL (1) | IL214112A0 (es) |
MX (1) | MX2011008452A (es) |
NI (1) | NI201100156A (es) |
PE (1) | PE20120603A1 (es) |
SG (1) | SG172986A1 (es) |
SV (1) | SV2011003993A (es) |
TW (1) | TW201033215A (es) |
UY (1) | UY32426A (es) |
WO (1) | WO2010092371A1 (es) |
ZA (1) | ZA201106625B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2759884A1 (en) * | 2009-05-11 | 2010-11-18 | Astrazeneca Ab | [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor |
DK2785349T4 (da) | 2011-11-30 | 2023-01-09 | Astrazeneca Ab | Kombinationsbehandling af cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
LT2894151T (lt) | 2012-09-04 | 2021-09-10 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje |
WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
NO2719005T3 (es) | 2014-07-28 | 2018-01-20 | ||
CR20170420A (es) | 2015-03-13 | 2017-10-03 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 |
EP3285764B1 (en) | 2015-03-31 | 2024-03-27 | University of Vermont and State Agricultural College | Triazolopyridazines for treating cryptosporidiosis |
ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
US11664093B2 (en) * | 2019-01-17 | 2023-05-30 | The Board Of Trustees Of The University Of Illinois | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning |
JP7183842B2 (ja) * | 2019-02-08 | 2022-12-06 | 富士通株式会社 | 結合自由エネルギー計算の前処理方法、前処理装置及び前処理プログラム、並びに、結合自由エネルギーの算出方法 |
CN114341125A (zh) * | 2019-05-02 | 2022-04-12 | 星座制药公司 | Trex1调节剂 |
WO2020243378A1 (en) * | 2019-05-31 | 2020-12-03 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods comprising endothelin a receptor antagonists and androgen therapies |
US20220227771A1 (en) * | 2020-12-30 | 2022-07-21 | Industrial Technology Research Institute | Androgen receptor binding molecule and use thereof |
CA3217423A1 (en) | 2021-06-16 | 2022-12-22 | Jeffrey M. Schkeryantz | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Vegfインヒビターとしてのキナゾリン誘導体 |
PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
KR100838617B1 (ko) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU2001266233B2 (en) | 2000-07-07 | 2006-06-29 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
CZ200331A3 (cs) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje |
ES2381781T3 (es) | 2002-02-01 | 2012-05-31 | Astrazeneca Ab | Compuestos de quinazolina |
US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
CN1597671A (zh) * | 2004-07-20 | 2005-03-23 | 贵州大学 | 喹唑啉衍生物及制备方法和生物活性 |
CA2582447C (en) * | 2004-10-01 | 2012-04-17 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
NZ568666A (en) * | 2005-11-30 | 2011-09-30 | Vertex Pharma | [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met |
CA2642205C (en) | 2006-02-10 | 2015-01-27 | Janssen Pharmaceutica N.V. | Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators |
EP1991223B1 (en) | 2006-02-10 | 2010-07-14 | Janssen Pharmaceutica, N.V. | Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators |
WO2007138472A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
TW200817409A (en) | 2006-08-04 | 2008-04-16 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
CN101563339A (zh) * | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物 |
WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
AU2007309237B2 (en) * | 2006-10-23 | 2012-03-22 | Sgx Pharmaceuticals, Inc. | Triazolo-pyridazine protein kinase modulators |
WO2008109104A1 (en) * | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
FR2919870B1 (fr) | 2007-08-09 | 2014-05-16 | Sanofi Aventis | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet |
PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
EP2235010A1 (en) | 2007-12-21 | 2010-10-06 | AstraZeneca AB | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
CA2759884A1 (en) | 2009-05-11 | 2010-11-18 | Astrazeneca Ab | [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor |
-
2010
- 2010-02-08 CN CN201080016898.1A patent/CN102388048B/zh active Active
- 2010-02-08 EP EP10703945.5A patent/EP2396333B1/en active Active
- 2010-02-08 EA EA201101180A patent/EA019647B1/ru not_active IP Right Cessation
- 2010-02-08 AU AU2010212590A patent/AU2010212590B2/en not_active Ceased
- 2010-02-08 KR KR1020117019968A patent/KR20110113755A/ko not_active Application Discontinuation
- 2010-02-08 MX MX2011008452A patent/MX2011008452A/es active IP Right Grant
- 2010-02-08 SG SG2011051034A patent/SG172986A1/en unknown
- 2010-02-08 ES ES10703945T patent/ES2427917T3/es active Active
- 2010-02-08 PE PE2011001469A patent/PE20120603A1/es not_active Application Discontinuation
- 2010-02-08 JP JP2011549665A patent/JP5059977B2/ja active Active
- 2010-02-08 CA CA2749926A patent/CA2749926A1/en not_active Abandoned
- 2010-02-08 WO PCT/GB2010/050191 patent/WO2010092371A1/en active Application Filing
- 2010-02-09 TW TW099104022A patent/TW201033215A/zh unknown
- 2010-02-09 AR ARP100100350A patent/AR075383A1/es unknown
- 2010-02-09 US US12/702,603 patent/US8258140B2/en active Active
- 2010-02-09 UY UY0001032426A patent/UY32426A/es not_active Application Discontinuation
-
2011
- 2011-07-14 IL IL214112A patent/IL214112A0/en unknown
- 2011-08-09 NI NI201100156A patent/NI201100156A/es unknown
- 2011-08-09 CL CL2011001920A patent/CL2011001920A1/es unknown
- 2011-08-10 EC EC2011011257A patent/ECSP11011257A/es unknown
- 2011-08-10 CU CU20110158A patent/CU20110158A7/es unknown
- 2011-08-10 CR CR20110427A patent/CR20110427A/es unknown
- 2011-08-10 DO DO2011000258A patent/DOP2011000258A/es unknown
- 2011-08-10 SV SV2011003993A patent/SV2011003993A/es unknown
- 2011-08-16 CO CO11103913A patent/CO6410299A2/es not_active Application Discontinuation
- 2011-09-09 ZA ZA2011/06625A patent/ZA201106625B/en unknown
-
2012
- 2012-06-08 HK HK12105648.1A patent/HK1164870A1/xx not_active IP Right Cessation
- 2012-08-01 US US13/564,029 patent/US20130203714A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP11011257A (es) | 2011-09-30 |
AR075383A1 (es) | 2011-03-30 |
MX2011008452A (es) | 2011-12-16 |
AU2010212590B2 (en) | 2013-01-10 |
TW201033215A (en) | 2010-09-16 |
US20100267699A1 (en) | 2010-10-21 |
JP2012517462A (ja) | 2012-08-02 |
HK1164870A1 (en) | 2012-09-28 |
AU2010212590A1 (en) | 2011-08-04 |
CL2011001920A1 (es) | 2011-10-21 |
US8258140B2 (en) | 2012-09-04 |
WO2010092371A1 (en) | 2010-08-19 |
CO6410299A2 (es) | 2012-03-30 |
NI201100156A (es) | 2012-03-19 |
CU20110158A7 (es) | 2012-02-15 |
US20130203714A1 (en) | 2013-08-08 |
UY32426A (es) | 2010-09-30 |
EP2396333B1 (en) | 2013-07-03 |
EA019647B1 (ru) | 2014-05-30 |
ZA201106625B (en) | 2013-02-27 |
EP2396333A1 (en) | 2011-12-21 |
CN102388048B (zh) | 2014-07-30 |
CN102388048A (zh) | 2012-03-21 |
PE20120603A1 (es) | 2012-06-14 |
CR20110427A (es) | 2011-09-21 |
ES2427917T3 (es) | 2013-11-04 |
KR20110113755A (ko) | 2011-10-18 |
JP5059977B2 (ja) | 2012-10-31 |
EA201101180A1 (ru) | 2012-03-30 |
IL214112A0 (en) | 2011-08-31 |
CA2749926A1 (en) | 2010-08-19 |
SV2011003993A (es) | 2012-01-06 |
SG172986A1 (en) | 2011-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000258A (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata | |
CR20110610A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
CL2012001180A1 (es) | Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras. | |
CO7240375A2 (es) | Compuestos tricíclicos sustituidos como inhibidores del fgfr | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
CR20120031A (es) | Derivados de 5-fluoropirimidinona | |
UY31728A (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica | |
GT201400213A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
ECSP14013215A (es) | Compuestos novedosos | |
NI201100198A (es) | [1, 2, 4] triazolo [4, 3 - b] piridazinas como ligandos del receptor de andrógenos | |
CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
CR20150171A (es) | Benzamidas | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY31689A1 (es) | Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica | |
ECSP12011651A (es) | Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
SV2011003784A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. | |
ECSP12012047A (es) | Derivados de 2-aldoximino-5-fluoropirimidina | |
UY32154A (es) | Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia | |
CR11640A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
CU20080030A7 (es) | Ih-imidazopiridinas sustituidas con hidroxi y procedimientos |